Vandenbroucke laat na farma-industrie voldoende te controleren
![Foto: iStock. Vandenbroucke laat na farma-industrie voldoende te controleren](/sites/default/files/styles/snov_news_header_novs_w28/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=WBqUMXbV 28w, /sites/default/files/styles/snov_news_header_novs_w33/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=NmWa3s4g 33w, /sites/default/files/styles/snov_news_header_novs_w39/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=lLL5naxW 39w, /sites/default/files/styles/snov_news_header_novs_w47/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=_sOTjiTN 47w, /sites/default/files/styles/snov_news_header_novs_w56/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=p4p5bD9D 56w, /sites/default/files/styles/snov_news_header_novs_w66/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=hhkXMEIF 66w, /sites/default/files/styles/snov_news_header_novs_w67/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=HkHknOt- 67w, /sites/default/files/styles/snov_news_header_novs_w78/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=QE6ZboAe 78w, /sites/default/files/styles/snov_news_header_novs_w79/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=Ir6ssl-O 79w, /sites/default/files/styles/snov_news_header_novs_w94/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=jCcdGkiY 94w, /sites/default/files/styles/snov_news_header_novs_w111/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=W3m0TejH 111w, /sites/default/files/styles/snov_news_header_novs_w112/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=pPKlZi0w 112w, /sites/default/files/styles/snov_news_header_novs_w131/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=MakjqYUP 131w, /sites/default/files/styles/snov_news_header_novs_w134/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=55ZLU4wn 134w, /sites/default/files/styles/snov_news_header_novs_w155/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=mf2UdYkJ 155w, /sites/default/files/styles/snov_news_header_novs_w158/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=VuWj6GdW 158w, /sites/default/files/styles/snov_news_header_novs_w183/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=SUk4CGeC 183w, /sites/default/files/styles/snov_news_header_novs_w188/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=sRoE5vWB 188w, /sites/default/files/styles/snov_news_header_novs_w216/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=ig6Kq2cg 216w, /sites/default/files/styles/snov_news_header_novs_w222/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=PpGjoIJy 222w, /sites/default/files/styles/snov_news_header_novs_w255/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=MuYnbXxJ 255w, /sites/default/files/styles/snov_news_header_novs_w262/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=0UILgkWl 262w, /sites/default/files/styles/snov_news_header_novs_w300/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=xVJa35HG 300w, /sites/default/files/styles/snov_news_header_novs_w310/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=zzY77L5w 310w, /sites/default/files/styles/snov_news_header_novs_w353/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=WJVYVEO2 353w, /sites/default/files/styles/snov_news_header_novs_w366/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=5cOkvPDw 366w, /sites/default/files/styles/snov_news_header_novs_w416/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=c6XWMftU 416w, /sites/default/files/styles/snov_news_header_novs_w432/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=wxyiMzKH 432w, /sites/default/files/styles/snov_news_header_novs_w490/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=9K6oUxSG 490w, /sites/default/files/styles/snov_news_header_novs_w510/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=JYzKzbJV 510w, /sites/default/files/styles/snov_news_header_novs_w577/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=Rsv0RP9R 577w, /sites/default/files/styles/snov_news_header_novs_w600/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=EuNd5JHa 600w, /sites/default/files/styles/snov_news_header_novs_w679/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=Epal_NGE 679w, /sites/default/files/styles/snov_news_header_novs_w706/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=9F2rbtaW 706w, /sites/default/files/styles/snov_news_header_novs_w799/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=FhYTkxxc 799w, /sites/default/files/styles/snov_news_header_novs_w832/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=Ztyu84bk 832w, /sites/default/files/styles/snov_news_header_novs_w941/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=z_UD7uq_ 941w, /sites/default/files/styles/snov_news_header_novs_w980/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=7iWVqJlo 980w, /sites/default/files/styles/snov_news_header_novs_w1108/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=UGx-LKU7 1108w, /sites/default/files/styles/snov_news_header_novs_w1154/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=WGjTRmBo 1154w, /sites/default/files/styles/snov_news_header_novs_w1304/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=4TFgnUG8 1304w, /sites/default/files/styles/snov_news_header_novs_w1358/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=gTKMx2_Y 1358w, /sites/default/files/styles/snov_news_header_novs_w1535/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=O2VgrkG- 1535w, /sites/default/files/styles/snov_news_header_novs_w1598/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=3LVnBDzm 1598w, /sites/default/files/styles/snov_news_header_novs_w1806/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=fISeIdKN 1806w, /sites/default/files/styles/snov_news_header_novs_w1882/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=oFNUJ70Y 1882w, /sites/default/files/styles/snov_news_header_novs_w2125/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=0w3KkJW_ 2125w, /sites/default/files/styles/snov_news_header_novs_w2216/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=VA-3CU-s 2216w, /sites/default/files/styles/snov_news_header_novs_w2500/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=VQ2mhAZW 2500w, /sites/default/files/styles/snov_news_header_novs_w2608/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=VM0NJCmP 2608w, /sites/default/files/styles/snov_news_header_novs_w3070/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=b33-RHxI 3070w, /sites/default/files/styles/snov_news_header_novs_w3612/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=5HH8lDKf 3612w, /sites/default/files/styles/snov_news_header_novs_w4250/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=bGUhxbwj 4250w, /sites/default/files/styles/snov_news_header_novs_w5000/public/2023-07/iStock-1248493102%20%281%29.jpg?h=5bfa1ac3&itok=ny2kWuBj 5000w)
Het Vlaams Belang is niet te spreken over de exploderende kosten voor nieuwe kankermedicijnen. “Minister van Volksgezondheid Frank Vandenbroucke (Vooruit) gaat hierin zeker niet vrijuit”, zegt Kamerlid Dominiek Sneppe. “Hij heeft steeds nagelaten de nodige controle uit te oefenen op de farmaceutische bedrijven.”
Cijfers die De Morgen opvroeg bij het RIZIV tonen ontegensprekelijk aan dat kankermedicijnen in dit land zo goed als onbetaalbaar zijn geworden. Het gaat de voorbije jaren om een spectaculaire stijging. In 2014 gaf het RIZIV 338,3 miljoen euro uit aan innovatieve geneesmiddelen, in 2021 ging het al om 1,4 miljard. “Mensen die door kanker getroffen worden, hebben uiteraard alles, en dus ook al hun middelen over in hun strijd tegen die vreselijke ziekte”, aldus Sneppe. “Hiervan mag door de farmaceutische industrie op geen enkele wijze geprofiteerd worden.”
“Farmaceutische bedrijven moeten de meerwaarde van de medicijnen kunnen verantwoorden”
“Het ontbreken van een goed onderhandeld farmaplan is één van de oorzaken van de onaanvaardbare prijsstijgingen”, vervolgt Sneppe. “Maar daarnaast is ook de ziekenhuisfinanciering een boosdoener. Die zorgt er immers voor dat oncologen beloond worden wanneer ze meer innovatieve geneesmiddelen voorschrijven. En dat kan niet de bedoeling zijn, zeker omdat ondertussen voldoende rapporten, zoals van Federaal Kenniscentrum voor de Gezondheidszorg en het Europees Geneesmiddelenbureau, aantonen dat de nieuwe medicatie vaak niet tot levensverlenging of levensverbetering leidt.” Een uitgebreide analyse van het Europees Geneesmiddelenbureau gaf aan dat nauwelijks een derde van de medicijnen zorgde een kleine levensverlenging, en slechts één tiende voor een verbeterde levenskwaliteit.
Het Vlaams Belang eist dat Vandenbroucke veel meer controle uitoefent op de farmaceutische bedrijven. “De minister heeft er momenteel geen enkel zicht op welke klinische onderzoeken deze bedrijven doen en wat daarvan de resultaten zijn”, besluit Sneppe. “Door de bedrijven toe te laten hun geneesmiddelen snel op de markt te brengen, zonder dat de meerwaarde ervan verantwoord moet worden, zet Vandenbroucke de deur open voor misbruik, waar tenslotte alleen de farmaceutische industrie beter van wordt en zeker niet de patiënt.”